References
- World Health Organization. Framework for Implementing New Tuberculosis Diagnostics. WHO, Geneva, Switzerland (2010).
- Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med.363(11), 1005–1015 (2010).
- Boehme CC, Nicol MP, Nabeta P et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet377(9776), 1495–1505 (2011).
- Chegou NN, Hoek KG, Kriel M, Warren RM, Victor TC, Walzl G. Tuberculosis assays: past, present and future. Expert Rev. Anti Infect. Ther.9(4), 457–469 (2011).
- Vassall A, van Kampen S, Sohn H et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost–effectiveness analysis. PLoS Med.8(11), e1001120 (2011).
- Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, UK (2005).
- Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch. Intern. Med.163(14), 1637–1641 (2003).
- Commission on macroeconomics and health. Macroeconomics and Health: Investing in Health for Economic Development. WHO, Geneva, Switzerland (2001).
- Dowdy DW, Cattamanchi A, Steingart KR, Pai M. Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med.8(7), e1001063 (2011).
- Stall N, Rubin T, Michael JS et al. Does solid culture for tuberculosis influence clinical decision making in India? Int. J. Tuberc. Lung Dis.15(5), 641–646 (2011).
- World Health Organization. Roadmap for Rolling Out Xpert® MTB/RIF for Rapid Diagnosis of TB and MDR-TB. WHO, Geneva, Switzerland (2010).
- Baltussen R, Floyd K, Dye C. Cost–effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ331(7529), 1364 (2005).
- Sanders GD, Hlatky MA, Owens DK. Cost–effectiveness of implantable cardioverter-defibrillators. N. Engl. J. Med.353(14), 1471–1480 (2005).
- Philips Z, Ginnelly L, Sculpher M et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol. Assess.8(36), iii–iv, ix–xi, 1–158 (2004).
- Dowdy DW, OBrien MA, Bishai D. Cost–effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int. J. Tuberc. Lung Dis.12(9), 1021–1029 (2008).
- Mueller DH, Mwenge L, Muyoyeta M et al. Costs and cost–effectiveness of tuberculosis cultures using solid and liquid media in a developing country. Int. J. Tuberc. Lung Dis.12(10), 1196–1202 (2008).
- Lin HH, Langley I, Mwenda R et al. A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools. Int. J. Tuberc. Lung Dis.15(8), 996–1004 (2011).
- Uplekar M, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet358(9285), 912–916 (2001).
- Wright A, Zignol M, Van Deun A et al. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet373(9678), 1861–1873 (2009).